Salvage surgery for advanced non-small cell lung cancer following previous immunotherapy: a retrospective study

Journal of Cardiothoracic Surgery

Research

Hikaru Yamaguchi¹  Hiroyuki Suzuki¹  Takuro Saito²  Sho Inomata³  Mitsunori Higuchi³ 

[1] Department of Chest Surgery, Fukushima Medical University School of Medicine, Fukushima, Japan;Department of Surgery, Aizu Medical Center, Fukushima Medical University, Aizuwakamatsu, Japan;Department of Thoracic Surgery, Aizu Medical Center, Fukushima Medical University, 21-2 Maeda, Tanisawa, Kawahigashi, 969-3492, Aizuwakamatsu, Japan;

关键词: Non-small cell lung cancer (NSCLC);    Salvage surgery;    Immune checkpoint inhibitor (ICI);    Downstaging;    Prognosis;   

DOI  :  10.1186/s13019-023-02310-5

 received in 2023-03-08, accepted in 2023-06-28,  发布年份 2023

来源: Springer

【 摘 要 】

BackgroundThe development of systemic chemotherapy including immune checkpoint inhibitors (ICIs) has provided patients with unresectable advanced non-small cell lung cancer (NSCLC) an opportunity to undergo surgical intervention after initial treatment. However, no consensus regarding the indication for salvage surgery in these patients has been reached.MethodsWe conducted a retrospective study of patients who underwent salvage surgery for advanced NSCLC (cStage IIIA–IVB) after treatment with ICIs from January 2018 to December 2022 at Aizu Medical Center and Fukushima Medical University Hospital. We evaluated the patients’ clinical data, calculated disease-free survival (DFS) and overall survival (OS), and assessed the survival benefit using the Kaplan–Meier method.ResultsThirteen patients underwent salvage surgery after immunotherapy. All patients achieved downstaging after initial chemotherapy. Eleven patients underwent lobectomy, and one patient underwent extirpation of intra-abdominal lymph nodes. The mean surgery time and intraoperative blood loss were 242.2 min and 415.1 g, respectively. The mean drainage period was 4.2 days (range, 2–9 days). Grade ≥ 3 postoperative complications were confirmed in three patients. The 2-year DFS rate was 71.2%, and the 2-year OS rate was 76.2%. A pathological complete response compatible with ypStage 0 was achieved in four (30.8%) patients. Patients with ypStage 0 and I achieved significantly better OS than those with ypStage ≥ II (p = 0.044), and patients without severe complications achieved significantly better DFS and OS than those with severe complications (p = 0.001 and p < 0.001, respectively).ConclusionsSalvage surgery after chemotherapy including ICIs is a feasible and effective treatment option for patients with advanced NSCLC, especially those who acquire downstaging to pathological stage 0 or I. However, severe perioperative complications might affect patient survival. A prospective study is urgently needed to evaluate the efficacy of salvage surgery.

【 授权许可】

CC BY   
© The Author(s) 2023

【 图 表 】

13570_2023_282_Article_IEq4.gif

Fig. 5

Fig. 6

Fig. 2